Screener
Dyne Therapeutics, Inc. DYN Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by Dyne Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Dyne Therapeutics, Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 7:25 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-215702
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Interest expense | (4,202) | — |
| Other expense, net | (133) | (89) |
| Total other income, net | 4,422 | 7,011 |
| Net loss | $(120,854) | $(115,361) |
| Net loss per share—basic and diluted | $(0.73) | $(1.05) |
| Weighted average common shares outstanding, basic and diluted | 165,036,604 | 109,911,628 |
| Comprehensive loss: | ||
| Net loss | $(120,854) | $(115,361) |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Dyne Therapeutics, Inc.'s net income?
- Dyne Therapeutics, Inc. (DYN) reported net income of -$120.85M in Q1 2026.
- How has Dyne Therapeutics, Inc.'s net income changed year-over-year?
- Dyne Therapeutics, Inc.'s net income decreased by 4.8% year-over-year, from -$115.36M to -$120.85M.
- What is the long-term trend for Dyne Therapeutics, Inc.'s net income?
- Over 4 years (2021 to 2025), Dyne Therapeutics, Inc.'s net income has grown at a 31.5% compound annual growth rate (CAGR), from -$149.29M to -$446.21M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about Dyne Therapeutics, Inc.'s net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude